HomeAI · summaries
Storia in 2 fonti
Argenx Analyst Is Bullish Despite Changes To Phase 3 Myositis Study - argenx (NASDAQ:ARGX)
HC Wainwright sees over $1 billion in sales potential for Argenx's Vyvgart in IMNM despite myositis trial changes.
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
investors.com
Can Argenx Retake Its Record High On A New Vyvgart Strategy?
Investors digested its myositis-focused R&D Day.
- ·
benzinga.com
Argenx Analyst Is Bullish Despite Changes To Phase 3 Myositis Study - argenx (NASDAQ:ARGX)
HC Wainwright sees over $1 billion in sales potential for Argenx's Vyvgart in IMNM despite myositis trial changes.